This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Terlipressin

Mallinckrodt plc

Drug Names(s): terlipressin, Haemopressin, Variquel (EU), Lucassin (Australia)

Description: Terlipressin is a synthetic 12 amino acid peptide (1-triglycyl-8-lysine-vasopressin) derived from the natural hormone lysine-vasopressin. Due to its constrictive activity on vascular and extra-vascular smooth muscle cells (V-1 agonist), it reduces blood flow in the splanchnic area, and thereby lowers portal blood pressure.

Deal Structure: Specialty European Pharma and Proreo
In February 2007, Specialty European Pharma announced that it has acquired Proreo Pharma International AG. The acquisition of Proreo Pharma provides the Company with access to Haemopressin.

Maelor (IS Pharma) and Specialty European Pharma
In March 2008, Maelor plc announces the acquisition of Specialty European Pharma International AG, a wholly owned subsidiary of Specialty European Pharma Limited. The Company is also proposing to change its name to International Specialty Pharmaceuticals (IS Pharma).

In April 2008, IS Pharma announced that the Company has completed its acquisition of Specialty European Pharma International AG.

Orphan Therapeutics and IS Pharma
Orphan Therapeutics is developing terlipressin in the US under a license from Specialty European Pharma, now IS Pharma. Orphan will pay IS Pharma a royalty on sales.

ESP Pharma and Orphan Therapeutics
ESP Pharma acquired exclusive marketing...See full deal structure in Biomedtracker

Partners: Orphan Therapeutics, LLC Sinclair IS Pharma plc


Terlipressin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug